Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L At University Of Pennsylvania

December 28th, 2007 | Category: Womens Health

Northwest Biotherapeutics, Inc. (OTC Bulletin Board: NWBO) (AIM: NWBT; NWBS) (”NWBT”) announced that a Phase I/II clinical trial in at least 30 patients, using DCVax(R)-L for recurrent ovarian cancer, has begun at The University of Pennsylvania Center for Research on Early Detection and Cure

of Ovarian Cancer and the Abramson Cancer Center. The first patients have been enrolled and have undergone initial treatment steps in preparation for receiving DCVax(R)-L. [click link for full article]

Original post by Women’s Health / Gynecology News From Medical News Today

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.